scholarly journals Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies

2017 ◽  
Vol 93 (3) ◽  
pp. 401-407 ◽  
Author(s):  
Courtney D. DiNardo ◽  
Caitlin R. Rausch ◽  
Christopher Benton ◽  
Tapan Kadia ◽  
Nitin Jain ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Combination Therapy ◽  
Clinical Experience ◽  
Myeloid Leukemia ◽  
Myeloid Malignancies ◽  
Refractory Acute Myeloid Leukemia ◽  
Acute Myeloid

scholarly journals A Phase Ib Study of Onvansertib, a Novel Oral PLK1 Inhibitor, in Combination Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia

2020 ◽  
Vol 26 (23) ◽  
pp. 6132-6140
Author(s):  
Amer M. Zeidan ◽  
Maya Ridinger ◽  
Tara L. Lin ◽  
Pamela S. Becker ◽  
Gary J. Schiller ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Combination Therapy ◽  
Myeloid Leukemia ◽  
Phase Ib ◽  
Refractory Acute Myeloid Leukemia ◽  
Acute Myeloid

Venetoclax combination therapy in relapsed/refractory acute myeloid leukemia: A single institution experience

2020 ◽  
Vol 90 ◽  
pp. 106314 ◽  
Author(s):  
Daria Gaut ◽  
Aaron Burkenroad ◽  
Tuyen Duong ◽  
Jesse Feammelli ◽  
Joshua Sasine ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Combination Therapy ◽  
Myeloid Leukemia ◽  
Single Institution ◽  
Refractory Acute Myeloid Leukemia ◽  
Acute Myeloid

scholarly journals Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia

Blood ◽  
2017 ◽  
Vol 130 (6) ◽  
pp. 722-731 ◽  
Author(s):  
Eytan M. Stein ◽  
Courtney D. DiNardo ◽  
Daniel A. Pollyea ◽  
Amir T. Fathi ◽  
Gail J. Roboz ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Dose Escalation ◽  
Myeloid Leukemia ◽  
Selective Inhibitor ◽  
Myeloid Malignancies ◽  
Key Points ◽  
Refractory Acute Myeloid Leukemia ◽  
Acute Myeloid ◽  
Refractory Aml

Key Points Enasidenib, a selective inhibitor of mutant IDH2 enzymes, was safe and well tolerated in patients with IDH2-mutated myeloid malignancies. Enasidenib induced hematologic responses in patients with relapsed/refractory AML in this dose-escalation and expansion study.

Sign in / Sign up

Export Citation Format

Share Document